RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación
Artículo científico (JournalArticle)
High-Grade Glioma Treatment Response Monitoring Biomarkers: A Position Statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 2: Spectroscopy, Chemical Exchange Saturation, Multiparametric Imaging, and Radiomics
[EN] ObjectiveTo summarize evidence for use of advanced MRI techniques as monitoring biomarkers in the clinic, and to highlight the latest bench-to-bedside developments. MethodsThe current evidence regarding the potential for monitoring biomarkers was reviewed and individual modalities of metabolism and/or chemical composition imaging discussed. Perfusion, permeability, and microstructure imaging were similarly analyzed in Part 1 of this two-part review article and are valuable reading as background to this article. We appraise the clinic readiness of all the individual modalities and consider methodologies involving machine learning (radiomics) and the combination of MRI approaches (multiparametric imaging). ResultsThe biochemical composition of high-grade gliomas is markedly different from healthy brain tissue. Magnetic resonance spectroscopy allows the simultaneous acquisition of an array of metabolic alterations, with choline-based ratios appearing to be consistently discriminatory in treatment response assessment, although challenges remain despite this being a mature technique. Promising directions relate to ultra-high field strengths, 2-hydroxyglutarate analysis, and the use of non-proton nuclei. Labile protons on endogenous proteins can be selectively targeted with chemical exchange saturation transfer to give high resolution images. The body of evidence for clinical application of amide proton transfer imaging has been building for a decade, but more evidence is required to confirm chemical exchange saturation transfer use as a monitoring biomarker. Multiparametric methodologies, including the incorporation of nuclear medicine techniques, combine probes measuring different tumor properties. Although potentially synergistic, the limitations of each individual modality also can be compounded, particularly in the absence of standardization. Machine learning requires large datasets with high-quality annotation; there is currently low-level evidence for monitoring biomarker clinical application. ConclusionAdvanced MRI techniques show huge promise in treatment response assessment. The clinical readiness analysis highlights that most monitoring biomarkers require standardized international consensus guidelines, with more facilitation regarding technique implementation and reporting in the clinic., This publication is part of the COST Action CA18206 Glioma
MR Imaging 2.0 (www.glimr.eu), supported by COST (European
Cooperation in Science and Technology), www.cost.eu. GliMR provided travel and accommodation for members who had
travelled to early networking meetings.
- KS: National Institute of Health/National Cancer Institute R01
CA255123, U01 CA176110, UG3 CA247606, Medical College
of Wisconsin Cancer Center.
- GH: Austrian Science Fund grant KLI-646.
- ECW: The Dutch Research Council (NWO) Talent Programme
Veni: 18144
- EAHW: The Dutch Research Council (NWO) Talent Programme
Veni: 91619121
- PF: The Portuguese Foundation for Science and Technology (FCT)
Grant UIDB/50009/2020.
- RN: Babes-Bolyai University, Grant GTC No. 35277/18.11.2020.
- TB: The Wellcome/EPSRC Centre for Medical Engineering
[WT 203148/Z/16/Z].
- MA¿
-T: The ALBATROSS project (National Plan for Scientific
and Technical Research and Innovation 2017-2020 and
DPI2016-80054-R (Programa Estatal de Promocio¿n del
Talento y su Empleabilidad en I+D+i).
Proyecto:
Fundação para a Ciência e a Tecnologia / 6817 - DCRRNI ID UIDB/50009/2020
,
Portugal 18144
,
Netherlands Organization for Scientific Research 91619121
,
Netherlands Organization for Scientific Research WT 203148/Z/16/Z
,
Engineering and Physical Sciences Research Council CA18206
,
Reino Unido KLI-646
,
European Cooperation in Science and Technology DPI2016-80054-R
,
Austrian Science Fund R01 CA255123
,
Agencia Estatal de Investigación U01 CA176110
,
National Cancer Institute UG3 CA247606
,
EEUU 35277/18.11.2020